Antibe Therapeutics Inc. (OTCMKTS:ATBPF) Short Interest Update

Antibe Therapeutics Inc. (OTCMKTS:ATBPF) was the recipient of a significant increase in short interest in April. As of April 15th, there was short interest totalling 65,100 shares, an increase of 1,934.4% from the March 31st total of 3,200 shares. Based on an average trading volume of 92,600 shares, the days-to-cover ratio is currently 0.7 days.

Wall Street Analyst Weigh In

Separately, Brookline Capital Management downgraded Antibe Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, March 4th.

Antibe Therapeutics Stock Performance

Shares of Antibe Therapeutics stock opened at $0.22 on Friday. The stock has a fifty day simple moving average of $0.36 and a 200 day simple moving average of $0.53. Antibe Therapeutics has a 12-month low of $0.11 and a 12-month high of $0.89. The company has a market capitalization of $11.43 million, a P/E ratio of -0.86 and a beta of 0.51.

Antibe Therapeutics (OTCMKTS:ATBPF) last announced its quarterly earnings results on Wednesday, February 14th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.03. On average, analysts predict that Antibe Therapeutics will post -0.31 EPS for the current year.

About Antibe Therapeutics

Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs).